Crohn's & Colitis 360最新文献

{"title":"Impact of pediatric versus adult diagnosed inflammatory bowel disease on achievement of health care autonomy in emerging adults: a cross-sectional study.","authors":"Allison Bihari, Cynthia H Seow, Eytan Wine, Karen Goodman, Farhad Peerani, Frank Hoentjen, Lilian Du, Karen Wong, Brendan Halloran, Michal Gozdzik, Karen I Kroeker","doi":"10.1093/crocol/otag078","DOIUrl":"10.1093/crocol/otag078","url":null,"abstract":"<p><strong>Introduction: </strong>Emerging adulthood (ages 18-25) involves significant changes, made more challenging for those with inflammatory bowel disease (IBD), especially when transitioning from pediatric to adult care. Research has focused on transition readiness, with less attention to patient-prioritized outcomes after transfer. Less is also known about those diagnosed during emerging adulthood, who must navigate a new diagnosis and disease management. This study estimated the prevalence of behaviors reflecting health care autonomy among emerging adults with IBD, comparing pediatric- and adult-diagnosed cases.</p><p><strong>Methods: </strong>In this cross-sectional study, emerging adults with IBD in Alberta, Canada completed a questionnaire assessing IBD knowledge, self-management, relationship with their IBD care team, and disease management. Participants were grouped as pediatric-diagnosed (<18 years) or adult-diagnosed (18-25 years). Descriptive and comparative analyses were conducted.</p><p><strong>Results: </strong>Among 178 participants (122 pediatric-diagnosed; 56 adult-diagnosed), pediatric-diagnosed cases were younger on average than adult-diagnosed cases (21.0 vs. 22.2 years), with similar distributions of gender, ethnicity and disease type. IBD knowledge scores, relationship ratings, and medication adherence scores were similar between groups. Pediatric-diagnosed cases were less independent than adult-diagnosed cases in some self-management tasks, including scheduling visits (72.6% vs. 92.9%), contacting their care team (76.0% vs. 94.6%), calling in medication refills (75.5% vs. 90.7%), and preparing questions for providers (63.3% vs. 79.3%).</p><p><strong>Conclusion: </strong>Pediatric-diagnosed cases demonstrated similar IBD knowledge, medication adherence, and satisfaction with their care team, but were less independent in some self-management tasks compared to adult-diagnosed cases. These findings highlight the need for targeted education and support for emerging adults with IBD.</p>","PeriodicalId":10847,"journal":{"name":"Crohn's & Colitis 360","volume":"8 3","pages":"otag078"},"PeriodicalIF":1.8,"publicationDate":"2026-07-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13415457/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148618659","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ileocecal resection for primary Crohn's disease: a 17-year experience from a tertiary care hospital in North Africa.","authors":"Souhaib Atri, Mahdi Hammami, Ahmed Ben Mahmoud, Amine Sebai, Houcine Maghrebi, Wael Rebai, Youssef Chaker, Amine Makni, Amine Daghfous, Rachid Ksantini, Mohamed Jouini, Anis Haddad, Montassar Kacem","doi":"10.1093/crocol/otag077","DOIUrl":"10.1093/crocol/otag077","url":null,"abstract":"<p><strong>Introduction: </strong>Ileocecal resection (ICR) is the most common procedure for primary Crohn's disease. While outcomes of ICR have been extensively studied in Europe and North America, data from North Africa remains scarce. This study reports a 17-year Tunisian experience, evaluating the feasibility of laparoscopic ICR in a low-income country in comparison to open surgery.</p><p><strong>Methods: </strong>This retrospective, single-center study reviewed patients who underwent ICR for histologically confirmed Crohn's disease between 2004 and 2020. Postoperative outcomes of laparoscopic and open approaches were compared. The endpoint was postoperative morbidity and mortality, intraoperative parameters, and recovery metrics.</p><p><strong>Results: </strong>A total of 336 patients underwent surgery for non-recurrent ileocecal Crohn's disease, with laparoscopic resection performed in 80% of cases. Conversion to open surgery occurred in 14.9%, mainly due to hemorrhagic dissection. Postoperative complications occurred in 9.2% of patients, with anastomotic leakage being the most frequent surgical issue. Medical complications were rare (1.2%). Laparoscopy was associated with faster recovery, shorter hospital stays, and lower analgesic requirements, although complication rates were not significantly different. The only significant predictor of anastomotic fistula was low body mass index (BMI) (<i>P</i> < .001). Postoperative mortality was 0.5%.</p><p><strong>Conclusion: </strong>In low-income countries, including North Africa, access to laparoscopy has expanded, with outcomes such as conversion rates and operative times approaching international standards. In our 17-year Tunisian experience, laparoscopic ICR proved feasible, reproducible, and safe. These findings contribute to the limited regional evidence and support the broader adoption of laparoscopy as the preferred surgical approach for Crohn's disease.</p>","PeriodicalId":10847,"journal":{"name":"Crohn's & Colitis 360","volume":"8 3","pages":"otag077"},"PeriodicalIF":1.8,"publicationDate":"2026-07-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13449604/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148697241","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Standard malnutrition screening tools inadequately capture comprehensive nutritional needs in outpatients with inflammatory bowel disease.","authors":"Aileen Xu, Michelle Schneider, Elisabeth Gorecki, Sonya Dave, Chanelle Chua, Poonam Beniwal-Patel","doi":"10.1093/crocol/otag054","DOIUrl":"10.1093/crocol/otag054","url":null,"abstract":"<p><strong>Background: </strong>Malnutrition is common in inflammatory bowel disease (IBD) patients and associated with worse outcomes and quality of life. This study aimed to assess the feasibility of referring outpatient IBD patients with qualifying modified malnutrition universal screening tool (mMUST) scores to in-person registered dietitian (RD) evaluations. The secondary aim was to analyze the nutritional data collected.</p><p><strong>Methods: </strong>IBD patients seen at a tertiary care center between August and December 2022 were screened with the mMUST. Those with mMUST ≥1 were referred to an RD for comprehensive nutritional evaluation. Data were extracted via chart review and analyzed using <i>t</i>-tests and Fisher's exact tests.</p><p><strong>Results: </strong>Of 1698 patients, 990 (58%) were screened with the mMUST. Of those who screened positive and were referred, 19 (20%) completed RD evaluations. Among these, 37% consumed less than 75% of the nutritional needs. Body mass indices were evenly distributed between low, normal, and high. Though 26% of patients met a formal definition for moderate or severe protein-calorie malnutrition, 53% had muscle depletion and 42% had fat depletion.</p><p><strong>Conclusions: </strong>A simple screening tool can identify IBD patients at risk for malnutrition; however, patient- and provider-sided barriers prevent appropriate evaluation. The RD evaluations revealed body composition changes and signs of malnutrition that were not reflected in weight or routine labs. These findings highlight the need for routine malnutrition screening and comprehensive dietitian evaluation for all at-risk IBD patients, not just those who appear underweight or frail.</p>","PeriodicalId":10847,"journal":{"name":"Crohn's & Colitis 360","volume":"8 3","pages":"otag054"},"PeriodicalIF":1.8,"publicationDate":"2026-07-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13375260/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148469224","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Highlights of the 2026 European Crohn's and Colitis Conference: redefining the IBD care continuum.","authors":"Ahmed Al-Hindawi, Alexander Siegel, Clive Jude Miranda, Gautam Maddineni, Mohammad Shehab","doi":"10.1093/crocol/otag075","DOIUrl":"10.1093/crocol/otag075","url":null,"abstract":"<p><strong>Introduction and purpose: </strong>Inflammatory bowel disease (IBD) care is moving from a symptom-driven step-up model of care toward earlier effective intervention, complication-specific management, and more personalized treatment selection. This review synthesizes selected ECCO 2026 studies and offers an expert appraisal of their clinical relevance, methodological strengths, and remaining uncertainties. Particular emphasis is placed on studies most likely to influence current practice and further research, including late-breaking trials, complication-directed therapy, pediatric evidence, and technology-assisted assessment.</p><p><strong>Summary of findings: </strong>Study findings spanned both ulcerative colitis (UC) and Crohn's disease (CD). New therapeutic studies presented included the phase 3 study of vedolizumab in pediatric UC, phase 2 efficacy data for picankibart in UC, and regenerative fistula data of AVB-114 in perianal CD. Real-world data presented included comparative data on different Janus kinase inhibitors in UC. Updates on interleukin-23 included durable extension data in UC, as well as efficacy data in advanced therapy‑exposed patients (mirikizumab in UC and risankizumab in CD). Innovative technologies included transperineal ultrasound for early identification of steroid non-response in acute severe UC, and multimodal artificial intelligence for Mayo endoscopic scoring. Beyond drug therapy, the 10-year LIR! C follow-up provided further data on surgical intervention as an early strategy in selected uncomplicated ileal CD, while the Preventing IBD ONset in Individuals at Risk study investigated potential benefits of a whole-food diet in high-risk first-degree relatives.</p><p><strong>Conclusion and next steps: </strong>ECCO 2026 emphasized durable, precision-oriented, multidisciplinary, and technology-enabled IBD care across the full continuum, from prevention to long-term modification. Apart from phase 3 and extension trials, other results remain preliminary and need broader comparative and practice-embedded studies before widespread adoption.</p>","PeriodicalId":10847,"journal":{"name":"Crohn's & Colitis 360","volume":"8 3","pages":"otag075"},"PeriodicalIF":1.8,"publicationDate":"2026-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13399156/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148583545","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Remote monitoring to improve engagement for patients with inflammatory bowel disease: a randomized clinical trial.","authors":"Shivan J Mehta, Phuoc Nguyen, Caitlin Brophy, Catherine Reitz, Christopher K Snider, Meenakshi Bewtra, James D Lewis","doi":"10.1093/crocol/otag076","DOIUrl":"10.1093/crocol/otag076","url":null,"abstract":"<p><strong>Background: </strong>Biologic therapy has improved care for patients with inflammatory bowel disease (IBD), but adherence is often suboptimal, and a gap in care is lack of engagement between visits. We evaluated the effect of a behaviorally-informed remote text monitoring program on outcomes and adherence among patients with IBD.</p><p><strong>Methods: </strong>Adults with IBD and receiving biologics through home health or self-injection were individually randomized 1:1 to control (usual care) or intervention (remote monitoring), stratified by medication type (home infusion vs. injection). The 4-month intervention included the following components via text message: (1) biologic dose reminders, (2) medication adherence check-ins after each dose, (3) weekly symptom check-ins with escalation to the patient's care team if above threshold, and (4) feedback to an identified support partner (when applicable). The primary outcome was change in quality of life via the Short Inflammatory Bowel Disease Questionnaire (SIBDQ).</p><p><strong>Results: </strong>150 patients were enrolled; 148 completed the study, and 144 were analyzed for the survey outcomes (73 control, 71 intervention). The mean age was 38.9, 52.7% were female, and 81.1% were White. No significant differences were found between arms for the change in median score from baseline to end of study for the SIBDQ, MARS-5, or patient satisfaction surveys. Medication adherence remained high across both arms, and there was no significant difference in the proportion of days covered for infusion or injection between arms.</p><p><strong>Conclusions: </strong>Remote monitoring was feasible with high patient satisfaction, but there was no improvement in quality of life or medication adherence.</p><p><strong>Trial registration: </strong>clinicaltrials.gov NCT04388865.</p>","PeriodicalId":10847,"journal":{"name":"Crohn's & Colitis 360","volume":"8 3","pages":"otag076"},"PeriodicalIF":1.8,"publicationDate":"2026-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13384052/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148600032","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Partial enteral nutrition combined with an exclusion diet promotes a healthy gut microbiome in patients with mild to moderately active ulcerative colitis: a quasi-experimental study.","authors":"Sudheer K Vuyyuru, Divya Madan, Sourav Goswami, Bhaskar Kante, Omprakash Shete, Peeyush Kumar, Mukesh Kumar Ranjan, Sandeep Mundhra, Rithvik Golla, Himanshu Narang, Nitika Monga, Namrata Singh, Govind Makharia, Tarini Shankar Ghosh, Saurabh Kedia, Vineet Ahuja","doi":"10.1093/crocol/otag068","DOIUrl":"10.1093/crocol/otag068","url":null,"abstract":"<p><strong>Background and aims: </strong>The therapeutic role of enteral nutrition and diet in patients with ulcerative colitis (UC) has not been adequately explored. We aimed to evaluate the effectiveness of partial enteral nutrition (PEN) in combination with an exclusion diet (ED) in patients with UC.</p><p><strong>Methods: </strong>In this prospective, open-label, non-randomized, quasi-experimental study, patients with mild-to-moderate UC (simple clinical colitis activity index [SCCAI]3-9) were non-randomly allocated to either PEN+ED along with standard of care (SOC) or SOC alone for 4 weeks. The primary outcome was clinical remission (SCCAI ≤2) at week 4. In addition, fecal microbiota analysis was performed at baseline and at week 4 for 14 participants in the PEN+ED group.</p><p><strong>Results: </strong>Sixty patients were included (PEN+ED = 30; SOC = 30). Baseline disease activity parameters were similar between the two groups. At week 4, 66.7% (20/30) of patients in the PEN+ED arm achieved clinical remission compared to 83.3% (25/30) receiving SOC. The proportion of patients with rectal bleeding score \"0\" was significantly lower in PEN+ED (56.7% vs 86.7%, <i>P</i> = .01) arm at week 4. A numerically higher number of patients required steroids in SOC arm compared to the PEN+ED arm, but it was not significant (23.3% vs 16.7%, <i>P</i> = .748). Microbiome analysis showed significant improvements in alpha diversity, increased relative abundance of beneficial gut microbes, depletion of pathobionts, and shift toward a healthier microbial profile, which was in turn shown to be negatively associated with disease severity.</p><p><strong>Conclusions: </strong>Although PEN+ED does not appear to have additional clinical benefit to SOC at week 4, it was associated with significant improvement in gut microbiota. Long-term benefits of dietary interventions should be explored in future studies.</p><p><strong>Clinical trial registration number: </strong>ISRCTN15559229.</p>","PeriodicalId":10847,"journal":{"name":"Crohn's & Colitis 360","volume":"8 3","pages":"otag068"},"PeriodicalIF":1.8,"publicationDate":"2026-07-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13371756/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148454993","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The PANACEA Project: a multinational model for digital health literacy in inflammatory bowel disease.","authors":"Viviana Parra Izquierdo, Beatriz Iade Vergara, Marta Benner Machado, Ginary Orduz Diaz, Carolina Samper, Juan Sebastian Frías-Ordoñez, Jahir Soto Mora, Guillermo Veitia","doi":"10.1093/crocol/otag055","DOIUrl":"10.1093/crocol/otag055","url":null,"abstract":"<p><strong>Background: </strong>Inflammatory bowel disease (IBD) represents an increasing public health challenge in Latin America, where structural inequities and limited access to standardized education contribute to gaps in health literacy. Despite the recognized role of patient education in IBD care, region-wide, structured digital initiatives remain limited.</p><p><strong>Objective: </strong>To describe the implementation, reach, and educational performance of PANACEA (PANamerican Crohn's and Colitis Educational Approach), a multinational digital education program for patients with IBD and caregivers in Latin America.</p><p><strong>Methods: </strong>We conducted a multicenter observational descriptive study evaluating four consecutive PANACEA cohorts delivered between 2024 and 2025 through an asynchronous e-learning platform. Adults with IBD or caregivers voluntarily enrolled and completed standardized pre- and post-module knowledge assessments and satisfaction surveys. Program adherence, baseline characteristics, knowledge change, normalized learning gain, and user satisfaction were analyzed using descriptive statistics.</p><p><strong>Results: </strong>A total of 1366 participants from 15 Latin American countries completed baseline assessments (mean age 41.4 years; 80% female). Sustained adherence to the platform was 53.1%. Cohorts with intermediate baseline knowledge demonstrated improvements in program-specific knowledge assessments (absolute improvement 8-9 points; normalized gain 0.43-0.52), while cohorts with high baseline scores exhibited ceiling effects. Participants with lower baseline knowledge tended to demonstrate greater relative improvements in knowledge scores. Satisfaction exceeded 90% across content quality, usability, and perceived usefulness.</p><p><strong>Conclusions: </strong>This observational evaluation demonstrates that PANACEA is a feasible and scalable digital education model for IBD in Latin America, achieving broad regional reach, high user satisfaction, and improvements in program-specific knowledge scores, particularly among participants with lower baseline knowledge levels.</p>","PeriodicalId":10847,"journal":{"name":"Crohn's & Colitis 360","volume":"8 3","pages":"otag055"},"PeriodicalIF":1.8,"publicationDate":"2026-07-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13371765/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148454929","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"One-year dynamics of clinical activity during biologics therapy in patients of ulcerative colitis.","authors":"Yizhe Tie, Fengyuan Su, Jianwu Zhang, Minhui Zheng, Ningyi Li, Jieqi Zheng, Minhu Chen, Rirong Chen, Li Li, Shenghong Zhang","doi":"10.1093/crocol/otag074","DOIUrl":"10.1093/crocol/otag074","url":null,"abstract":"<p><strong>Background: </strong>Longitudinal trajectories and the optimal timing for evaluating clinical activity remains unclear in ulcerative colitis (UC) patients receiving biologics.</p><p><strong>Methods: </strong>This study included 2705 UC patients from 5 trials and collected 28 807 records of partial Mayo scores (PMS) from baseline to week 52. Latent class growth mixed model was performed to construct 1-year PMS trajectories. Logistic regression assessed the association between PMS trajectories and 1-year therapeutic outcomes, and endoscopic remission was the primary outcome. Spearman correlation was utilized to identify the timepoints of PMS most correlated with the trajectories.</p><p><strong>Results: </strong>Five trajectories of clinical activity were identified, including rapid remission (<i>n</i> = 590, 21.8%), delayed remission (<i>n</i> = 316, 11.7%), mild improvement (<i>n</i> = 748, 27.7%), slow improvement (<i>n</i> = 915, 33.8%), and relapse-fluctuation (<i>n</i> = 136, 5.0%) groups. Endoscopic and histological remission rates exhibited a progressive decline across trajectory groups, with the highest probability in the rapid remission group and sequentially lower probabilities in the delayed remission, mild/slow improvement, and relapse-fluctuation groups (<i>P</i> < .001). Week-20 PMS demonstrated the strongest correlation with clinical activity trajectories (correlation coefficient = 0.7867, <i>P</i> < .001), with an area under curve of 0.9311 (95% CI: 0.9183, 0.9440). Furthermore, week-20 PMS could independently predicted 1-year endoscopic (aOR [95% CI] 0.59 [0.54, 0.65], <i>P</i> < .001) and histological (aOR [95% CI] 0.61 [0.53-0.70], <i>P</i> < .001) remission.</p><p><strong>Conclusions: </strong>UC patients receiving biologics would exhibit 5 distinct trajectories of clinical activity. Week 20 is a potential intermediate timepoint for clinical activity assessment to inform long-term outcomes.</p>","PeriodicalId":10847,"journal":{"name":"Crohn's & Colitis 360","volume":"8 3","pages":"otag074"},"PeriodicalIF":1.8,"publicationDate":"2026-07-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13384053/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148600105","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparative effectiveness of adalimumab versus infliximab in children with Crohn's disease: real-world data from the prospective PIBD-SETQuality inception cohort study.","authors":"Stephanie A Vuijk, Renz C W Klomberg, Eva Katgert, Margreet M S Wessels, Erasmo Miele, Fiona L Cameron, Ivan D Milovanovich, Rafeeq Muhammed, David Devadason, James Hart, Dimitris Rizopoulos, Nicholas M Croft, Lissy de Ridder","doi":"10.1093/crocol/otag069","DOIUrl":"10.1093/crocol/otag069","url":null,"abstract":"<p><strong>Background: </strong>Infliximab and adalimumab are effective anti-tumor necrosis factor (anti-TNF) therapies for the treatment of pediatric Crohn's disease (CD). The aim of this study was to compare the effectiveness of infliximab and adalimumab in a real-world cohort of children with CD.</p><p><strong>Methods: </strong>Data from biological-naïve children with luminal CD (age 3-18 years) who commenced anti-TNF and completed at least 1 year of follow-up were collected from the prospective multicenter observational PIBD-SETQuality study. The primary outcome was steroid-free clinical remission (SFCR), defined as clinical remission (weighted pediatric Crohn's disease activity index [wPCDAI] <12.5) without systemic steroids or luminal surgery at 1 year. The relative risk (RR) of SFCR was calculated using standardization, correcting for the following baseline covariates: age, upfront anti-TNF, C-reactive protein, erythrocyte sedimentation rate, albumin, leukocytes, disease behavior, wPCDAI, perianal disease, and concomitant immunomodulator use. Secondary outcomes included the durability of anti-TNF treatment without luminal surgery.</p><p><strong>Results: </strong>Between January 1, 2017, and June 14, 2024, 178 patients with anti-TNF were included (infliximab: <i>n</i> = 121 [68%], adalimumab: <i>n</i> = 57 [32%]). At 12 months, 34/56 (61%) patients treated with adalimumab and 66/120 (55%) patients treated with infliximab had reached SFCR. The RR of SFCR at 1 year with adalimumab compared to infliximab was 1.25 (95% confidence interval [CI] 0.94-1.66], <i>P</i> = .13. Adalimumab was associated with a significant lower adjusted hazard ratio (aHR) of treatment discontinuation than infliximab in patients with a concomitant immunomodulator (aHR 0.17 [95% CI 0.04-0.75], <i>P</i> = .020), adjusted for upfront anti-TNF.</p><p><strong>Conclusions: </strong>In this prospective cohort of children with CD, adalimumab and infliximab showed comparable clinical effectiveness 1 year after the start of anti-TNF treatment.</p><p><strong>Clinical trial registration: </strong>The ClincalTrials.gov ID of this study is NCT03571373.</p>","PeriodicalId":10847,"journal":{"name":"Crohn's & Colitis 360","volume":"8 3","pages":"otag069"},"PeriodicalIF":1.8,"publicationDate":"2026-07-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13431788/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148668550","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluating the impact of inflammatory bowel disease on mental health during pregnancy: a retrospective survey study.","authors":"Nikhila Butani, Serena Perera, Varun Srikanth, Vrati Mehra, Katie O'Connor, Karren Xiao, Yash Patel, Cynthia Maxwell, Nadia Griller, Talia Zenlea, Vithyaa Premjeyanth, Simone Vigod, Vivian Huang","doi":"10.1093/crocol/otag070","DOIUrl":"10.1093/crocol/otag070","url":null,"abstract":"<p><strong>Background: </strong>Individuals with inflammatory bowel disease (IBD) experience mental health disorders at rates 1.5-2 times higher than the general population. Many are affected during major life stages such as pregnancy, yet data on how IBD influences anxiety and depression in pregnancy remain limited.</p><p><strong>Methods: </strong>This retrospective survey study included patients from the \"Preconception and Pregnancy in IBD\" clinic who conceived before January 1, 2022. Standardized pre-visit surveys assessed anxiety (general anxiety disorder-7 [GAD-7]), depression (patient health questionnaire-9 [PHQ-9]), and IBD activity using pMayo6 for ulcerative colitis (UC) and mHBI for Crohn's disease (CD). Demographic variables included age, marital and employment status, smoking, alcohol and cannabis use, prior anxiety/depression diagnoses, IBD subtype, surgical history, and medication use. Linear regression models evaluated associations between disease activity and mental health outcomes, adjusting for medication type and stratifying by trimester and IBD subtype.</p><p><strong>Results: </strong>Ninety-four patients were included: 42 patients had UC (44.7%), and 52 patients had CD (55.3%). Median age was 32 (interquartile range [IQR] 31-35.8) for UC and 32.7 (IQR 30-35.2) for CD. Active UC in the second trimester was associated with significantly higher anxiety (<i>P</i> = 0.034) and depression (<i>P</i> = 0.022) scores compared to those with inactive UC. In the third trimester, this pattern persisted, with active UC again associated with elevated anxiety (<i>P</i> = 0.030) and depression (<i>P</i> = 0.027) scores. Active CD in the second trimester was significantly associated with higher anxiety (<i>P</i> = 0.024) and depression scores (<i>P</i> = 0.021) compared to those in remission.</p><p><strong>Conclusions: </strong>Active IBD during pregnancy is significantly associated with increased anxiety and depression. Multidisciplinary care, including mental health support, is imperative for pregnant people with IBD.</p>","PeriodicalId":10847,"journal":{"name":"Crohn's & Colitis 360","volume":"8 3","pages":"otag070"},"PeriodicalIF":1.8,"publicationDate":"2026-07-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13455083/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148705632","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}